News & PR

RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial

2016.01.29

RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial

(if you want to view the body of article, click on the bottom link)

http://www.prnewswire.com/news-releases/regenerx-announces-completion-of-patient-enrollment-in-phase-2b3-us-dry-eye-trial-300212101.html

Modify Delete List

15개(1/1Page)

News & PR
No	Subject	Date
15	ReGenTree Announces the Results of the ARISE-2 Trial With RGN-259 for the Treatment of Dry Eye: Significant Ef...	2017.10.31
14	RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017	2017.05.09
13	RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259...	2016.11.09
12	RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye	2016.05.06
11	RegeneRx and ReGenTree Expand License for Dry Eye	2016.04.28
>>	RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial	2016.01.29
9	RegeneRx U.S. Joint Venture, ReGenTree, Launches Web Site	2016.01.28
8	RegeneRx Updates on U.S. Ophthalmic Clinical Trials	2015.10.21
7	RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RG...	2015.09.21
6	RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259	2015.09.16
5	RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S...	2015.04.16
4	RegeneRx Joint Venture Partner Receives $7.28 million USD From Korean Government and Venture Fund for U.S. Dev...	2015.03.09
3	RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S.	2015.01.28

처음페이지

이전 10 페이지

1

다음 10 페이지

마지막페이지